Testing a new immune therapy for advanced neuroendocrine cancers

Plain-English translation of NCT07080242 on ClinicalTrials.gov ↗ · Source last updated October 2026 · Translation generated September 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new medication called to see if it can help treat advanced neuroendocrine cancers that have spread or grown locally. These cancers include small cell lung cancer, certain prostate cancers, pancreatic cancers, and Merkel cell carcinoma. The medication works by targeting a protein called DLL3, which is often found on these cancer cells.

Neuroendocrine cancers are aggressive and hard to treat, and many patients run out of options when standard chemotherapy stops working. This trial is exploring whether this new treatment could help patients whose cancer has already resisted at least one round of prior therapy.

Do you qualify?

You likely qualify if…

you have been diagnosed with locally advanced or metastatic neuroendocrine cancer (such as small cell lung cancer, prostate cancer, pancreatic cancer, lung cancer, or Merkel cell carcinoma)
your cancer has failed at least one prior round of standard treatment, or you are unable to receive standard chemotherapy
your cancer cells show evidence of DLL3 protein expression
you have at least one measurable tumor that can be tracked on scans
you are in good enough overall health (ECOG performance status 0–1) and have adequate heart, liver, and kidney function
any side effects from your previous cancer treatment have resolved to Grade 1 or better

You likely don't qualify if…

you have received a prior topoisomerase inhibitor-based antibody-drug conjugate therapy
you have received chemotherapy, immunotherapy, or targeted therapy within the past 4 weeks
you have active or untreated brain metastases requiring steroids or seizure medication
you have significant lung disease (such as poorly controlled COPD, asthma, or pulmonary hypertension)
you have severe heart problems or a reduced heart ejection fraction (below 50%)

What participation looks like

If you qualify, you would receive the medication as an intravenous infusion on Day 1 of each 3-week cycle. The trial will monitor your safety and how your body responds to the treatment through blood tests, scans, and clinic visits. You would continue treatment as long as the medication is helping and you are tolerating it well, with the goal of understanding whether this new approach can slow or shrink your cancer.

AI-generated summary from trial data · Sep 20, 2026 · Not medical advice

Trial locations(31 sites)

United States

Clearview Cancer Institute, Huntsville, Alabama

OPN Healthcare, Glendale, California

MemorialCare Long Beach Medical Center, Long Beach, California

Valkyrie Clinical Trials, Los Angeles, California

UCLA, Los Angeles, California